colforsin daropate

Colforsin daropate is a **water-soluble derivative of forskolin**, developed for cardiovascular applications. It is mainly used as a **cardiotonic drug** for the treatment of **acute heart failure**, acting as a potent **adenylate cyclase activator**. Through activation of adenylate cyclase, it increases intracellular cyclic AMP, leading to positive inotropic and vasodilator effects[5][2][1]. Recent research indicates colforsin daropate also exhibits anticancer activities, notably against **high-grade serous ovarian cancer (HGSOC)**, by inducing cell cycle arrest and apoptosis selectively in cancer cells, inhibiting **MYC signaling**—an important oncogenic pathway in ovarian cancer. Colforsin daropate has shown synergy with cisplatin and may sensitize cisplatin-resistant tumors[1][3]. It has negligible toxicity in non-cancerous cells and may be repurposed for cancer therapy[1][3]. The compound is formally a carboxylic ester of forskolin and N,N-dimethyl-beta-alanine[5].

Brand names

Colforsin daropate

Other names

Colforsin daropate hydrochlorideColforsin dapropate hydrochlorideNKH477NKH-477NKH 4776-(3-Dimethylaminopropionyl)forskolin hydrochlorideAdehlUNII-C6P4R272GTUNII-C-6P4R272GTUNII-C 6P4R272GT